Contribute Try STAT+ Today

Last month, the Italian government asked the World Health Assembly to adopt a resolution to require drug makers to disclose their R&D and production costs, as well as prices charged for medicines and vaccines. Italian health minister Giulia Grillo wrote to the World Health Organization that “international action is required to improve transparency” in order to widen access to pharmaceuticals. If the resolution is enacted, the WHO would have a mandate to collect and analyze data on clinical trial outcomes, assess patents, and provide a forum for countries to share information on prices, R&D and marketing costs, R&D subsidies, and public sector investments. In effect, the proposal would set an international standard, but is likely to get pushback from the pharmaceutical industry. We spoke with Grillo, who publicly announced the move on Tuesday, about the effort. Her comments are from both an email exchange and a phone conversation. This interview has been lightly edited.

Pharmalot: Why did you propose this resolution?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • What a cogent final sentence – “This is not going to be a love affair.”
    Ciao, Bella!

Comments are closed.

Your daily dose of news in health and medicine

Privacy Policy